Quince Therapeutics Inc., a biotechnology company focused on treating rare diseases, has announced a private placement of securities expected to generate approximately $11.5 million in upfront proceeds. The financing, led by Nantahala Capital and involving existing stockholders like ADAR1 Capital Management and Quince's senior management, could potentially raise an additional $10.4 million if the accompanying warrants are fully exercised. Priced at a premium to the last close, the funds are intended for working capital, general corporate purposes, and to support the ongoing Phase 3 NEAT clinical trial in Ataxia-Telangiectasia. Combined with existing resources, this financing is expected to support Quince's operations until mid-2026 or beyond, depending on warrant exercise.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。